• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    1/30/23 4:31:09 PM ET
    $ASLN
    $ATNX
    $BCLI
    $CALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASLN alert in real time by email

    Gainers

    • Nymox Pharmaceutical (NASDAQ:NYMX) shares rose 21.8% to $0.5 during Monday's after-market session. The market value of their outstanding shares is at $45.2 million.
    • Brainstorm Cell (NASDAQ:BCLI) stock rose 10.83% to $1.93. The company's market cap stands at $70.6 million.
    • OKYO Pharma (NASDAQ:OKYO) stock moved upwards by 6.46% to $2.8. The company's market cap stands at $60.9 million.
    • Creative Medical Tech (NASDAQ:CELZ) stock rose 6.28% to $0.57. The market value of their outstanding shares is at $8.0 million.
    • Athenex (NASDAQ:ATNX) stock rose 5.44% to $0.19. The company's market cap stands at $29.8 million.
    • Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 5.28% to $0.78. The company's market cap stands at $9.9 million.

    Losers

    • Xilio Therapeutics (NASDAQ:XLO) stock fell 9.3% to $3.6 during Monday's after-market session. The market value of their outstanding shares is at $98.8 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares declined by 8.2% to $1.12. The company's market cap stands at $8.8 million.
    • Integer Holdings (NYSE:ITGR) shares fell 7.41% to $65.5. The company's market cap stands at $2.1 billion.
    • Heart Test Laboratories (NASDAQ:HSCS) stock declined by 6.39% to $2.2. At the close, Heart Test Laboratories's trading volume reached 2.6 million shares. This is 6319.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $18.3 million.
    • ASLAN Pharma (NASDAQ:ASLN) shares declined by 5.77% to $0.64. The market value of their outstanding shares is at $44.6 million.
    • Calithera Biosciences (NASDAQ:CALA) stock fell 5.66% to $0.42. The market value of their outstanding shares is at $2.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ASLN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASLN
    $ATNX
    $BCLI
    $CALA

    CompanyDatePrice TargetRatingAnalyst
    OKYO Pharma Limited
    $OKYO
    2/20/2026$7.00Overweight
    Piper Sandler
    Integer Holdings Corporation
    $ITGR
    2/20/2026$95.00Hold → Buy
    The Benchmark Company
    OKYO Pharma Limited
    $OKYO
    12/8/2025$5.00Buy
    B. Riley Securities
    Integer Holdings Corporation
    $ITGR
    10/24/2025Buy → Hold
    Argus
    Integer Holdings Corporation
    $ITGR
    10/24/2025$80.00Overweight → Equal Weight
    Wells Fargo
    Integer Holdings Corporation
    $ITGR
    10/24/2025$77.00Buy → Neutral
    Citigroup
    Integer Holdings Corporation
    $ITGR
    10/24/2025$87.00Buy → Neutral
    BofA Securities
    Integer Holdings Corporation
    $ITGR
    10/24/2025Buy → Hold
    The Benchmark Company
    More analyst ratings

    $ASLN
    $ATNX
    $BCLI
    $CALA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on OKYO Pharma with a new price target

    Piper Sandler initiated coverage of OKYO Pharma with a rating of Overweight and set a new price target of $7.00

    2/20/26 8:25:04 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Integer Holdings upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded Integer Holdings from Hold to Buy and set a new price target of $95.00

    2/20/26 8:20:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    B. Riley Securities initiated coverage on OKYO Pharma with a new price target

    B. Riley Securities initiated coverage of OKYO Pharma with a rating of Buy and set a new price target of $5.00

    12/8/25 8:35:27 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    SEC Filings

    View All

    SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc.

    10-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 5:26:31 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)

    3/31/26 4:16:24 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Integer Holdings Corporation

    SCHEDULE 13G/A - Integer Holdings Corp (0001114483) (Subject)

    3/27/26 9:55:06 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Global Ops and Manufactur Harris John A bought $115,500 worth of shares (1,650 units at $70.00), increasing direct ownership by 37% to 6,066 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/13/25 4:18:50 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP, Chief Financial Officer Smith Diron bought $74,967 worth of shares (1,116 units at $67.19), increasing direct ownership by 17% to 7,698 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:19:02 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Capps Cheryl C bought $106,720 worth of shares (1,600 units at $66.70), increasing direct ownership by 16% to 11,702 units (SEC Form 4)

    4 - Integer Holdings Corp (0001114483) (Issuer)

    11/10/25 8:16:21 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update

    Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidenceCompany highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteriaNEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update. "Our main priority continues to be advancing NurOwn

    3/31/26 4:01:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

    LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (

    3/31/26 7:34:00 AM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    HeartSciences' MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

    Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), a healthcare information technology ("HIT") company focused on advancing electrocardiography ("ECG" or "EKG") through the integration of artificial intelligence ("AI"), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category. MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records ("EHRs"), including

    3/25/26 8:30:00 AM ET
    $HSCS
    Industrial Specialties
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Haight Nelson M

    3 - Virax Biolabs Group Ltd (0001885827) (Issuer)

    3/31/26 3:15:09 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Shannon James Samuel

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    3/30/26 5:29:01 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kapito Aaron

    4 - Integer Holdings Corp (0001114483) (Issuer)

    3/25/26 9:38:52 PM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Leadership Updates

    Live Leadership Updates

    View All

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and busin

    3/23/26 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Integer Appoints James Flanagan and Aaron Kapito to Board of Directors

    ~ Enters into Cooperation Agreement with Irenic Capital Management ~  PLANO, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced that James Flanagan has been appointed to the Board of Directors (the "Board") as an independent director. Additionally, in connection with a cooperation agreement with Irenic Capital Management, LP (together with its affiliates, "Irenic"), Aaron Kapito has also been appointed to the Board. "The Board looks forward to welcoming James and Aaron as new independent directors and benefiting from their complementary perspectives

    3/12/26 8:00:00 AM ET
    $ITGR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

    Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli will lead the clinical and regulatory strategy to advance the company's development program in neuropathic corneal pain (NCP), leveraging urcosimod's FDA Fast Track designationThis appointment, following the recent CEO appointment, further strengthens OKYO's world-class ophthalmology leadership team LONDON and NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neur

    2/10/26 8:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Financials

    Live finance-specific insights

    View All

    OKYO Pharma Announces Chairman and Founder Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 10,119 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically

    3/19/26 12:00:00 PM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that John Brancaccio, Non-Executive Director, has acquired 5,000 of the Company's ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as

    3/19/26 10:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    OKYO Pharma Announces Chief Development Officer and Director Acquires Shares

    LONDON and NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed that Gary Jacob, Chief Development Officer and Director, has acquired 30,980 of the Company's ordinary shares on NASDAQ at $1.59, bringing his total holding to 108,920 shares. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammat

    3/19/26 7:00:00 AM ET
    $OKYO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASLN
    $ATNX
    $BCLI
    $CALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Virax Biolabs Group Limited

    SC 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)

    11/14/24 4:46:07 PM ET
    $VRAX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 4:30:23 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care